Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry

Inclusion Criteria: * Cytological diagnosis of acute myeloid leukemia (AML) with indication for a first-line allo-HSCTs transplant * Patient affiliated to the social security system * For women of childbearing age, use of reliable contraception throughout the study in accordance with the CPR of the drugs used. * The patient must be able to comply with study visits and per protocol procedures * Patient who has been informed of the study and has signed his informed consent Exclusion Criteria: * Person under guardianship or curatorship, or unable to understand the purpose of the study. * Hematologic malignancies other than AML * History of neoplasia with bone involvement (sarcoma, multiple myeloma, metastasis...) and/or any solid cancer less than 5 years old * History of fracture of the femoral neck prior to the diagnosis of hematologic malignancies * Known bone involvement related to AML at diagnosis * Primary or secondary osteoporosis known to the diagnosis of hematologic malignancies * Corticotherapy \> 3 months at a dose \> 7.5mg/day prior to the diagnosis of hematological disease * Autograft or anterior allograft * Pathologies influencing bone metabolism: known inflammatory rheumatism (rheumatoid arthritis, ...), primary hyperparathyroidism, chronic renal failure (GFR \< or = at 30ml / min / 1.73m2) * Pregnant or lactating woman